Editor’s Note: Michael first shared this easy-to-own, low-volatility play on legal weed back in October 2017. As he expected, the shares have been moving nicely upward since then. Today, he believes that this play still has room to grow, in advance of a massive cannabis stock trigger: California’s impending total legalization of marijuana on Jan. 1 (click here for a look at Michael’s sector research). Simply put, Michael thinks this is a stock every investor should own before California goes fully legal. Here’s why…
The legal cannabis sector is no longer the "Wild West"-style marketplace it was back in, say, 2013, but there's still plenty of volatility compared with the placid broader markets.
Then again, that's why the right pot stocks reward forward-thinking investors with triple- and quadruple-digit gains. In fact, there's a bevy of micro- and small-cap companies, any one of which could be the next mega-cap blockbuster – the long-sought-after "Starbucks of weed" or "Facebook of pot."
My Nova-X Report's Roadmap to Marijuana Millions model portfolio is chock full of those kinds of stocks. Right now, my paid-up members are sitting on gains as high as 915%… 520.6… 442.7%… and five more triple-digit winners. (If you'd like to find out how to take advantage of this green revolution and get in on opportunities like those, click here.)
But I don't want to leave anyone with the impression that the only way to make a killing on pot stocks is to buy small, volatile companies. The gains from my Scotts Miracle-Gro Co. (NYSE: SMG) and GW Pharmaceuticals Plc. (Nasdaq: GWPH) recommendations prove that just isn't the case.
Then there's the company I want to tell you about today.
It isn't likely to quadruple your money quickly, but you'll likely smash the market with double- and even triple-digit gains, and it pays a dividend that puts you way out ahead of inflation and low interest rates, too.
What's more, all kinds of small, legal cannabis companies are beating a path to its door for help with a very tricky problem…
This Was a "Watershed Industry Moment" for Pot Stocks
USA Today enthusiastically hailed Microsoft's June 2016 move into the legal marijuana business. I was excited, too.
No, the Redmond, Wash.-based tech juggernaut won't be marketing stony edibles or any potent new strains of weed.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.